Medicenna Therapeutics Corp. (NASDAQ:MDNA) Q3 2023 Earnings Conference Call February 7, 2023 8:30 AM ET

Company Participants

Dan Ferry - Investor Relations, LifeSci Advisors

Fahar Merchant - President and Chief Executive Officer

Liz Williams - Chief Financial Officer

Conference Call Participants

Charles Zhu - Guggenheim

Matt Biegler - Oppenheimer

David Martin - Bloom Burton

RK - H.C. Wainwright

Catherine Novack - Jones Research

David Bautz - Zacks Small-Cap Research

Operator

Hello and welcome to the Medicenna Therapeutics Fiscal Third Quarter Earnings Call. All participants are now in a listen-only mode. There will be a Q&A session at the end of the prepared remarks. Please be advised, that this call is being recorded at the company’s request.

I would now like to turn the call over to Dan Ferry of LifeSci Advisors. Thank you. Please go ahead.

Dan Ferry

Thank you, operator. And thank you all for participating in today’s conference call. This morning Medicenna issued a press release providing financial results and corporate updates for the quarter ended December 31, 2022. If you have not seen the press release, it is available on the Investor page of Medicenna’s website.

Before we begin, I would like to remind you that certain statements and information shared during this call constitute forward-looking information within the meaning of applicable securities laws. All statements other than statements of historical facts shared during this call, and that relate to the future operations of the company, and other statements that are not historical facts, including statements related to the clinical potential, development and tolerability and safety profiles, MDNA11, preliminary clinical data, the clinical potential and development of MDNA55, partnering efforts, cash runway, the presentation of additional data and other milestones and patent protection are forward-looking statements that are subject to risks and uncertainties.

There can be no assurance that such statements were proved to be accurate, and actual results and future events could differ materially from those anticipated in such events. Important factors that may cause the actual results to differ materially from the company’s expectations, include the risks detailed in the Annual Information Form and 20-F of the company and in other filings made by the company with applicable securities regulators from time to time in Canada and the United States.

Listeners are cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of the company. You are cautioned not to place undue reliance on any forward-looking information. Such information although considered reasonable by management may prove to be incorrect and actual results may differ materially from those anticipated.